Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen
significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) …

Abstract Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐
aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin …

Simple Summary The VELOUR randomized phase III trial established aflibercept (an anti-
angiogenic targeting VEGF-A, VEGF-B, and placenta growth factor) combined with FOLFIRI …

Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …

Aim To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin
and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer …

Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …

Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …

Background and objective Aflibercept; a decoy receptor for vascular endothelial growth
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …

Background Patients with metastatic colorectal cancer (mCRC) previously-treated with
oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to …

Purpose To evaluate the safety and effectiveness of aflibercept in combination with
fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic …